News Conference News AHA 2025 Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia Michael O'Riordan November 14, 2025
News Conference News ESC 2025 ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients Michael O'Riordan September 10, 2025
News Conference News ESC 2025 Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b Caitlin E. Cox August 31, 2025
News Conference News ESC Heart Failure 2025 HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM Todd Neale May 19, 2025
News Conference News ESC 2024 Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events Caitlin E. Cox August 31, 2024
News Conference News ACC 2024 Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing Michael O'Riordan April 12, 2024
News Conference News AHA 2023 Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study Michael O'Riordan November 13, 2023
News Conference News AHA 2022 ‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE Michael O'Riordan November 06, 2022
News Conference News ACC 2022 Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70 Michael O'Riordan April 07, 2022
News Conference News EAS 2020 Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank Michael O'Riordan October 07, 2020
News Conference News EAS 2019 Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role Michael O'Riordan June 07, 2019
News Conference News AHA 2018 Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study Shelley Wood November 11, 2018
News Conference News AHA 2016 PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad Michael O'Riordan November 15, 2016